

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) 3837.1US	Application Number To be assigned 09/901,836
Applicant Valerio et al.		Filing Date July 10, 2001	
Group Art Unit To be assigned 1632		J0997 U.S. PTO 09/901836 07/10/01	

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>Ama</i>	#6,033,908	3/7/00	Bout et al.			
<i>Ama</i>	#6,040,174	3/21/00	Imler et al.			

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
<i>Ama</i>	#FR2649119	1/4/91	France				
	#EP0496074	7/29/92	Europe				
	#WO/9222332	12/23/92	WO				
	#WO/9309221	5/13/93	WO				
	#WO/9416734	8/4/94	WO				
	#WO/9412626	6/9/94	WO				
	#WO/9526412	10/5/95	WO				
<i>Ama</i>	#WO/9700326	1/3/97	PCT				

OTHER DOCUMENTS		(Including Author, Title, Date, Pertinent Pages, Etc.)
<i>Ama</i>	#Boado, R.J. (1995) <u>Adv. Drug Deliv. Rev.</u> , 15:73-107.	
<i>Ama</i>	#Curiel et al. (1994) <u>Virology</u> , 198:577-585.	
<i>Ama</i>	#Etienne-Julian et al. (1992) <u>J. Gen Virol.</u> , (1992) 73: 3251-3255.	
<i>Ama</i>	#Friedmann, T. "Overcoming the obstacles to gene therapy." <u>Sci. Am.</u> June 1997 pp. 96-101.	
<i>Ama</i>	#Marin et al. (1994) <u>Gene Therapy</u> , 1(2):s15.	

EXAMINER <i>Anne-Marie Zalk</i>	DATE CONSIDERED 1/21/04
------------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

(2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 09/000,133

Filed: February 24, 1998

For: METHOD AND MEANS FOR TARGETED GENE DELIVERY which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.